CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) issued its earnings results on Thursday. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11), FiscalAI reports. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 176.90%. The firm had revenue of $1.29 million during the quarter.
CAMP4 Therapeutics Trading Up 2.8%
CAMP stock traded up $0.12 during mid-day trading on Friday, hitting $4.46. 35,697 shares of the company were exchanged, compared to its average volume of 71,324. The business has a 50 day simple moving average of $4.63 and a 200-day simple moving average of $4.61. The stock has a market capitalization of $231.59 million, a PE ratio of -1.89 and a beta of 0.04. CAMP4 Therapeutics has a 1-year low of $1.30 and a 1-year high of $7.75.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Leerink Partners raised their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Rodman & Renshaw assumed coverage on shares of CAMP4 Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.60.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC increased its holdings in shares of CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares during the period. Vivo Capital LLC increased its holdings in shares of CAMP4 Therapeutics by 8.3% during the fourth quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock worth $26,031,000 after purchasing an additional 325,000 shares during the period. Balyasny Asset Management L.P. bought a new position in shares of CAMP4 Therapeutics during the fourth quarter worth approximately $14,938,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of CAMP4 Therapeutics by 11.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider’s stock worth $13,374,000 after purchasing an additional 220,895 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of CAMP4 Therapeutics by 457.0% during the fourth quarter. Geode Capital Management LLC now owns 336,293 shares of the Wireless communications provider’s stock worth $2,063,000 after purchasing an additional 275,922 shares during the period.
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Read More
- Five stocks we like better than CAMP4 Therapeutics
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
